EC fines Teva €60.5m over pay-for-delay deal
27-11-2020
FTC’s $448m AbbVie win overturned
02-10-2020
Ascannio / Shutterstock.com
Twenty US states, the US Federal Trade Commission (FTC), and consumer groups have asked the Seventh Circuit of the US Court of Appeals to reconsider a case claiming that AbbVie strived to prevent competition to its immunosuppressant drug, Humira.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
USFTC, AbbVie, Humira, immunosuppressant, biosimilar, patent litigation, reverse payments, Supreme Court, biologic, settlement
